Perrigo Company PLC

Perrigo Company PLC(PRGO)股票分析

$16.630

+0.151 (+0.91%)收盘时

Loading chart…
最高
16.680
开盘
16.540
成交量加权均价
16.52
成交量
2.44M
市值
—
最低
16.260
成交额
40.31M
企业价值/息税折旧摊销前利润(TTM)
9.24

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief.

AI 分析 of Perrigo Company PLC (PRGO)

买入

Perrigo Company PLC is a good buy right now, trading at $16.63 with a forward P/E ratio of 5.97, suggesting it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong 20-day change of +22.64%, indicating positive momentum. However, investors should be cautious due to a recent net income loss of $398.6 million in Q1 2026, which poses a risk to future profitability.

分析师评级(18)

上行空间 +22.25%
持有
6 买入
11 持有
1 卖出
当前: 16.63
最低
18.00
平均
20.33
最高
23.00

JPMorgan

2026-02-27

目标价

$15

中性

Canaccord

2026-02-27

目标价

$17

买入

JPMorgan

2025-12-15

目标价

$18

中性

Canaccord

2025-11-06

目标价

$20

买入

JPMorgan

2025-11-06

目标价

$20

中性

估值指标

Perrigo Company PLC(PRGO)当前预期市盈率为 5.97,5 年平均预期市盈率为 10.60。

预期市盈率

低估
5 年均值 P/E
10.60
当前P/E
5.97
高估
14.57
低估
6.63

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
9.36
当前EV/EBITDA
9.24
高估
13.30
低估
5.43

预期市销率

低估
5 年均值 P/S
0.84
当前P/S
0.56
高估
1.10
低估
0.59

Alphio AI 对 PRGO 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%PRGO

$33.09

情景价格

基

基准

基准 · 50%PRGO

$30.61

情景价格

悲

悲观

悲观 · 25%PRGO

$29.15

情景价格

持有 PRGO 的大户

B

BW Gestao de Investimentos Ltda.

+ 持有PRGO

+2.45%

3个月收益率

S

Sound Income Strategies, LLC

+ 持有PRGO

-3.77%

3个月收益率

事件时间线

2026-10-09 (ET)

16:30:00

Rumor of Perrigo Takeover Highlighted in Blog

2026-08-05 (ET)

07:00:00

Company Lowers FY26 Revenue Outlook by 1.5%-5.5%

07:00:00

Company Reports Q2 Revenue of $1.02B, Exceeding Expectations

2026-06-30 (ET)

17:00:00

Perrigo Appoints Salman Amin and Omer Gajial as Independent Directors

2026-06-10 (ET)

13:40:00

Perrigo rumor highlighted in Betaville blog

资讯

PRGO 常见问题 —— 由 Alphio AI 解答

Perrigo Company plc is a pure-play self-care company. The Company provides health and wellness solutions. Its segments include Self Care, Specialty Care, and Infant Formula. Self Care comprises Upper Respiratory, Digestive Health, Pain & Sleep and Healthy Lifestyle product categories globally. Specialty Care comprises our Women's Health and Skin Health product categories globally. Infant Formula comprises the Infant Formula product category, which includes nutritional products designed to meet the dietary needs of infants. It provides a store-branded private label provider of self-care products in many categories, including upper respiratory, healthy lifestyle and women's health, along with brands including Opill and Mederma. Its Europe portfolio consists primarily of brands, including Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Its upper respiratory products include Nasonex 24HR Energy, Mucus DM, All Day Allergy, Nighttime Cold & Flu, and Allergy Relief. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Perrigo Company PLC is a good buy right now, trading at $16.63 with a forward P/E ratio of 5.97, suggesting it is undervalued compared to its earnings potential. Additionally, the stock has shown a strong 20-day change of +22.64%, indicating positive momentum. However, investors should be cautious due to a recent net income loss of $398.6 million in Q1 2026, which poses a risk to future profitability.

18 analysts cover PRGO: 6 rate it Buy, 11 Hold and 1 Sell. The average price target is 20.33.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易